Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P43026 (
lipopolysaccharide
)
62,215
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We investigated the functions of
adiponectin
, an adipocyte-specific secretory protein and a new member of the family of soluble defense collagens, in hematopoiesis and immune responses. Adiponectin suppressed colony formation from colony-forming units (CFU)-granulocyte-macrophage, CFU-macrophage, and CFU-granulocyte, whereas it had no effect on that of burst-forming units-erythroid or mixed erythroid-myeloid CFU. In addition,
adiponectin
inhibited proliferation of 4 of 9 myeloid cell lines but did not suppress proliferation of erythroid or lymphoid cell lines except for one cell line. These results suggest that
adiponectin
predominantly inhibits proliferation of myelomonocytic lineage cells. At least one mechanism of the growth inhibition is induction of apoptosis because treatment of acute myelomonocytic leukemia lines with
adiponectin
induced the appearance of subdiploid peaks and oligonucleosomal DNA fragmentation. Aside from inhibiting growth of myelomonocytic progenitors,
adiponectin
suppressed mature macrophage functions. Treatment of cultured macrophages with
adiponectin
significantly inhibited their phagocytic activity and their
lipopolysaccharide
-induced production of tumor necrosis factor alpha. Suppression of phagocytosis by
adiponectin
is mediated by one of the complement C1q receptors, C1qRp, because this function was completely abrogated by the addition of an anti-C1qRp monoclonal antibody. These observations suggest that
adiponectin
is an important negative regulator in hematopoiesis and immune systems and raise the possibility that it may be involved in ending inflammatory responses through its inhibitory functions. (Blood. 2000;96:1723-1732)
...
PMID:Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. 1096 70
Adiponectin, an adipocyte-derived hormone, attenuates the production of TNFalpha by activated human macrophages. In the present study, we used porcine blood-derived macrophages to test the hypothesis that the anti-inflammatory action of
adiponectin
includes suppression of IL6 and an induction of IL10. Adiponectin suppressed both TNFalpha and IL6 production in macrophages activated with
lipopolysaccharide
(P<0.01). In contrast,
adiponectin
increased IL10 expression (P<0.05) and augmented (P<0.05) the induction of this cytokine by
lipopolysaccharide
(
LPS
). Mechanistically, the attenuation of proinflammatory cytokine production by
adiponectin
was associated with an attenuation of the translocation of NFkappaB to the nucleus. Either
adiponectin
or inhibition of ERK1/2 with U0126 diminished the induction of IL6 by
LPS
(P<0.05), but the combination of
adiponectin
and the inhibitor did not further reduce IL6 production. In contrast, the inhibitory actions of
adiponectin
and a p38 MAPK inhibitor (SB203580) were additive (P<0.05). These data indicate that the anti-inflammatory actions of
adiponectin
include suppression of IL6 and induction of IL10. In addition, we provide evidence that some of the anti-inflammatory actions of
adiponectin
are mediated in part by suppression of NFkappaB signaling and ERK1/2 activity.
...
PMID:Adiponectin differentially regulates cytokines in porcine macrophages. 1503 90
Adiponectin is an adipocyte-derived hormone that has been implicated recently in the regulation of inflammation in immunocytes, and in lipid metabolism and glucose homeostasis in liver, skeletal muscle and adipocytes. However, information in non-rodent models is limited. We have cloned and sequenced the porcine
adiponectin
open reading frame and evaluated the regulation of
adiponectin
in vivo following
lipopolysaccharide
(
LPS
) or E. coli administration. The porcine sequence shares approximately 88, 86, 85 and 83% homology with the dog, human, cow and mouse
adiponectin
respectively, and 79-83% similarity with dog, human, cow and mouse proteins at the amino acid level, based on the translated porcine sequence and GenBank submissions for the other species. Relative serum
adiponectin
concentrations were not altered in pigs infused with E. coli, and mRNA expression in adipose tissue was not responsive to
LPS
. However, analysis of serum from very lean vs a substantially fatter genotype of pig indicated that relative circulating
adiponectin
concentrations are higher (P<0.01) in the lean pigs than in the fatter genotype, and that the difference is established relatively early in the growth curve. Also, incubating pig adipocytes for 6 h with recombinant pig
adiponectin
resulted in an approximately 30% reduction (P<0.05) in lipogenesis compared with adipocytes under basal conditions and with those incubated in the presence of insulin. This is the first report in any species that
adiponectin
antagonizes the incorporation of glucose carbon into lipid in the adipocyte, and provides additional evidence that
adiponectin
acts as an autocrine regulatory factor to regulate energy metabolism.
...
PMID:Cloning and expression of porcine adiponectin, and its relationship to adiposity, lipogenesis and the acute phase response. 1522 38
Adiponectin, an adipocytokine, has been identified in adipose tissue, and its receptors are widely distributed in many tissues, including the liver. The present study was performed to clarify the role of
adiponectin
in
lipopolysaccharide
(
LPS
)-induced liver injury using KK-Ay obese mice. We analyzed the effects of
adiponectin
pretreatment on liver injury induced by D-galactosamine/
LPS
(GalN/
LPS
) in KK-Ay obese mice. GalN/
LPS
treatment induced significant increases in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels in the blood, apoptotic and necrotic changes in hepatocytes, and/or showed a high degree of lethality. The GalN/
LPS
-induced liver injury was more pronounced in KK-Ay obese mice than in lean controls. Pretreatment with
adiponectin
ameliorated the GalN/
LPS
-induced elevation of serum AST and ALT levels and the apoptotic and necrotic changes in hepatocytes, resulting in a reduction in lethality. In addition, pretreatment with
adiponectin
attenuated the GalN/
LPS
-induced increases in serum and hepatic tumor necrosis factor alpha (TNF-alpha) levels and increased peroxisome proliferator-activated receptor (PPAR) alpha messenger RNA expression in the liver. Furthermore, abdominal macrophages from KK-Ay obese mice pretreated with
adiponectin
in vitro exhibited decreased
LPS
-induced TNF-alpha production compared with controls. Finally,
adiponectin
pretreatment also ameliorated TNF-alpha-induced liver injury. In conclusion, these findings suggest that
adiponectin
prevents
LPS
-induced hepatic injury by inhibiting the synthesis and/or release of TNF-alpha of KK-Ay obese mice.
...
PMID:Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. 1523 81
The aim of this study was to evaluate the impact of the lack of inducible NO synthase (iNOS) on body weight and adipose tissue mass as well as on plasma leptin and
adiponectin
in basal conditions and 6 h after
lipopolysaccharide
(
LPS
) administration in mice. Body weight was not different among male, six-week-old wild-type (WT) and iNOS-/- animals. However, the amount of epididymal white adipose tissue (EWAT) in iNOS-/- mice was significantly reduced (P<0.05). Circulating leptin and leptin mRNA in EWAT were decreased in iNOS-/- mice (P<0.05 and P<0.01, respectively). Plasma
adiponectin
and
adiponectin
mRNA were unchanged.
LPS
administration increased plasma leptin in both genotypes (P<0.05). Neither genotype nor treatment changed plasma
adiponectin
. In summary, iNOS-/- mice exhibited normal body weight but reduced adipose mass accompanied by hypoleptinemia. Leptin responsiveness to
LPS
in iNOS-/- mutants is preserved, showing that the
LPS
-induced rise in leptin is independent of the presence of functional iNOS. In addition, iNOS deficiency or
LPS
does not influence expression and circulating levels of
adiponectin
.
...
PMID:Reduced adipose tissue mass and hypoleptinemia in iNOS deficient mice: effect of LPS on plasma leptin and adiponectin concentrations. 1555 8
Obesity and insulin resistance are often associated with lower circulating
adiponectin
concentrations and elevated serum interleukin-6 (IL-6) and/or tumor necrosis factor-alpha (TNF-alpha). Adiponectin suppresses activation of nuclear factor-kappaB (NF-kappaB) in aortic endothelial cells and porcine macrophages. Accordingly, we hypothesized that
adiponectin
is an anti-inflammatory hormone and suppresses activation of NF-kappaB in adipocytes. Because peroxisome proliferator-activated receptor gamma2 (PPARgamma2) antagonizes the transcriptional activity of NF-kappaB, we determined whether
adiponectin
alters PPARgamma2 expression in pig adipocytes. In addition, we determined whether interferon-gamma alters the expression of PPARgamma2 in the presence or absence of
adiponectin
. Primary adipocytes from pig subcutaneous adipose tissue were treated with or without
lipopolysaccharide
(LPS; 10 microg/ml) and
adiponectin
(30 microg/ml), and nuclear extracts were obtained for gel shift assays to assess nuclear localization of NF-kappaB. Whereas LPS induced an increase in NF-kappaB activation,
adiponectin
suppressed both NF-kappaB activation and the induction of IL-6 expression by LPS (P<0.05). Similar results were obtained in 3T3-L1 adipocytes. In addition,
adiponectin
antagonized LPS-induced increase in TNF-alpha mRNA expression (P<0.05) and tended (P<0.065) to diminish its accumulation in the culture media in 3T3-L1 adipocytes. Adiponectin also induced an upregulation of PPARgamma2 mRNA (P<0.05). Although IFN-gamma did not reduce the basal expression of PPARgamma2, it suppressed PPARgamma2 induction by
adiponectin
(P<0.05). These findings indicate that
adiponectin
may be a local regulator of inflammation in the adipocyte and adipose tissue via its regulation of the NF-kappaB and PPARgamma2 transcription factors.
...
PMID:Adiponectin inhibits LPS-induced NF-kappaB activation and IL-6 production and increases PPARgamma2 expression in adipocytes. 1560 6
Adiponectin exerts anti-inflammatory effects via macrophages, suppressing the production of pro-inflammatory cytokines in response to bacterial
lipopolysaccharide
(
LPS
). Here, we provide experimental evidence that the "anti-inflammatory" effect of
adiponectin
may be due to an induction of macrophage tolerance: globular
adiponectin
(gAd) is a powerful inducer of TNF-alpha and IL-6 secretion in primary human peripheral macrophages, in the THP-1 human macrophage cell line, and in primary mouse peritoneal macrophages. Pre-exposure of macrophages to 10 microg/ml gAd rendered them tolerant to further gAd exposure or to other pro-inflammatory stimuli such as TLR3 ligand polyI:C and TLR4 ligand
LPS
, while pre-exposure to 1 microg/ml of and re-exposure to 10 microg/ml gAd unmasked its pro-inflammatory properties. GAd induced NF-kappaB activation and tolerance to further gAd or
LPS
exposure. Our data suggest that
adiponectin
constant presence in the circulation in high levels (in lean subjects) renders macrophages resistant to pro-inflammatory stimuli, including its own.
...
PMID:Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. 1611 11
The aim of this study was to determine the release and regulation of leptin, resistin and
adiponectin
from human placenta and fetal membranes, and maternal subcutaneous adipose tissue and skeletal muscle obtained from normal and gestational diabetes mellitus (GDM)-complicated pregnancies at the time of Cesarean section. Tissue explants were incubated in the absence (basal control) or presence of 10 mug/ml
lipopolysaccharide
(
LPS
), 10, 20 or 40 ng/ml tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6 and IL-8, 1 microM phorbol myristate acetate, 10, 20 and 40 mM glucose, 0.1, 1 and 10 microM insulin and 0.1 1 and 10 microM dexamethasone, progesterone and estrogen. After an 18-h incubation, the medium was collected and the release of leptin, resistin and
adiponectin
was quantified by ELISA. Human gestational tissues and maternal tissues released immunoreactive leptin, resistin and
adiponectin
; however, there was no difference in the release of either resistin or
adiponectin
between normal pregnant women and women with gestational diabetes. The release of leptin was significantly higher in placenta, amnion and choriodecidua obtained from normal pregnant women compared with women with GDM. However, in maternal tissues, the situation was reversed, with adipose tissue and skeletal muscle obtained from women with GDM releasing significantly greater amounts of leptin. In adipose tissue and skeletal muscle the release of leptin was significantly greater in insulin-controlled GDM compared with diet-controlled GDM, and leptin release from adipose tissue was significantly correlated with maternal body mass index. In all tissues tested, there was no effect of incubation with
LPS
, IL-6, IL-8 or TNF-alpha on leptin, resistin or
adiponectin
release. PMA significantly increased the release of resistin from placenta and adipose tissue. Insulin increased placental resistin release, whereas the hormones dexamethasone, progesterone and estrogen significantly decreased placental resistin release. The data presented in this study demonstrate that dysregulation of leptin metabolism and/or function in the placenta may be implicated in the pathogenesis of GDM. Furthermore, resistin release is greatly affected by a variety of inflammatory mediators and hormones.
...
PMID:Release and regulation of leptin, resistin and adiponectin from human placenta, fetal membranes, and maternal adipose tissue and skeletal muscle from normal and gestational diabetes mellitus-complicated pregnancies. 1613 65
Chronic ethanol feeding sensitizes Kupffer cells to activation by
lipopolysaccharide
(
LPS
), leading to increased production of tumor necrosis factor-alpha (TNF-alpha). Adiponectin treatment protects mice from ethanol-induced liver injury. Because
adiponectin
has anti-inflammatory effects on macrophages, we hypothesized that
adiponectin
would normalize chronic ethanol-induced sensitization of Kupffer cells to
LPS
-mediated signals. Serum
adiponectin
concentrations were decreased by 45% in rats fed an ethanol-containing diet for 4 wk compared with pair-fed rats. Adiponectin dose dependently inhibited
LPS
-stimulated accumulation of TNF-alpha mRNA and peptide in Kupffer cells from both pair- and ethanol-fed rats. Kupffer cells from ethanol-fed rats were more sensitive to both globular (gAcrp) and full-length
adiponectin
(flAcrp) than Kupffer cells from pair-fed controls with suppression at 10 ng/ml
adiponectin
after chronic ethanol feeding. Kupffer cells expressed both
adiponectin
receptors 1 and 2; chronic ethanol feeding did not change the expression of
adiponectin
receptor mRNA or protein. gAcrp suppressed
LPS
-stimulated ERK1/2 and p38 phosphorylation as well as IkappaB degradation at 100-1,000 ng/ml in Kupffer cells from both pair- and ethanol-fed rats. However, only
LPS
-stimulated ERK1/2 phosphorylation was sensitive to 10 ng/ml gAcrp. gAcrp also normalized
LPS
-stimulated DNA binding activity of early growth response-1 with greater sensitivity in Kupffer cells from rats fed chronic ethanol. In conclusion, these results demonstrate that Kupffer cells from ethanol-fed rats are more sensitive to the anti-inflammatory effects of both gAcrp and flAcrp. Suppression of
LPS
-stimulated ERK1/2 signaling by low concentrations of gAcrp was associated with normalization of TNF-alpha production by Kupffer cells after chronic ethanol exposure.
...
PMID:Adiponectin normalizes LPS-stimulated TNF-alpha production by rat Kupffer cells after chronic ethanol feeding. 1641 Mar 64
Adiponectin has anti-inflammatory and anti-atherogenic properties in addition to its acknowledged roles in insulin sensitivity and energy homeostasis. These properties include the suppression of
lipopolysaccharide
[LPS]-mediated inflammatory events. We demonstrated that both recombinant and native
adiponectin
directly bind LPS derived from three different bacteria. The interaction occurred at pH 5.0-6.0 and was inhibited by the presence of Ca(2+) and Mg(2+), but enhanced by the sequestration of these cations. Maximal binding occurred at pH 6.0 in the presence of ethylenediaminetetraacetic acid. Lipid A and C1q were not inhibitory, although LPS, heparin, zymosan, and individual sugars all inhibited the reaction. Periodate-mediated deglycosylation of
adiponectin
, and reduction and alkylation also inhibited binding. Since
adiponectin
infiltrates into [relatively] acidic sites of inflammation, it may act as a scavenging anti-inflammatory agent in atherosclerosis and vascular damage where LPS [and other pro-inflammatory molecules] are present.
...
PMID:Human adiponectin binds to bacterial lipopolysaccharide. 1643 Dec 17
1
2
3
4
5
6
7
8
9
10
Next >>